Key Takeaways
- 13% revenue growth, highest-ever quarterly profit: Revenue grew 13% YoY and net profit hit ₹251 crores, driven by momentum across domestic and international businesses.
- Novo Nordisk deal reshapes the obesity narrative: The exclusive semaglutide distribution partnership gives Emcure an early-mover advantage in India's obesity market ahead of a crowded post-LOE field.
- Margins on track for 150 bps expansion: EBITDA margin reached 19.3%, and management reaffirmed the full-year base-margin improvement target of ~150 bps, with H2 expected to be stronger.
- Zuventus buyout adds debt but full consolidation: Acquiring the remaining minority stake pushed out the debt-free timeline to end-FY27, but full consolidation unlocks back-end synergies.
- What to watch next quarter: The pace of Amphotericin B launches across Western Europe, early traction on Poviztra in India, and whether the Sanofi cardiac portfolio sustains its recovery.
The Novo Nordisk Partnership & Obesity Entry
- Exclusive second brand: Emcure will distribute Poviztra, Novo Nordisk's second brand of semaglutide, exclusively in India, giving it a branded entry into the obesity market before the post-loss-of-exclusivity crowd arrives.
- First-mover logic: Management expects the market to become very crowded post-LOE, so launching ahead of competition allows Emcure to shape the market and build brand recall rather than being lost in a wave of generics 4-5 months later.
- Global product, no local manufacturing: The product will continue to be imported as Novo's global formulation, which management sees as a benefit for patient access to a product used by millions worldwide.
- International plans unaffected: The Novo agreement places no restrictions on Emcure's own semaglutide plans outside India; filings in Canada remain on track for the end of this fiscal year.
- Chronic portfolio tailwind: Semaglutide fits into the chronic basket with treatment durations of 6-8 months, supporting the broader chronic ramp-up thesis.
Satish Mehta: "The partnership gives us an early entry in the obesity market versus the rest of the competition and positions Emcure to shape it."
Domestic Business
- Above-industry growth: Domestic revenue grew 11% YoY, higher than the industry, with strength across core segments of gynecology and cardiology.
- Newer segments ramping: Derma, consumer health and diabetes are growing as expected and contributing to the diversification of the domestic mix.
- Sanofi cardiac normalization: The acquired cardiac portfolio is now back in line with industry growth, and the synergy effect from growing Emcure's own brands alongside it is beginning to show.
- Sanofi diabetes outperforming: The diabetes portfolio is tracking better than targeted, as Sanofi had historically under-focused on it and Emcure's promotion is unlocking healthy growth.
- GST impact transitory: Q2 saw some industry-wide impact from GST changes; management expects domestic growth to return to double-digit levels going forward.
- Organic growth ambition: Organically, Emcure aims to grow at industry rates plus 100-200 basis points.
Vikas Thapar: "post-LOE, we anticipate a very crowded market in India. And so the ability to partner with Novo and launch this brand ahead of the competition and allowing ourselves to shape the market and have brand recall versus being lost in the crowd probably 4, 5 months down the line is something that we feel strongly will allow us to succeed."
International Markets
- Broad-based 16%+ growth: All geographies contributed, with Europe up 22%, Canada up 17%, and Rest of World driven by teens-level growth in the non-ARV segment.
- Europe driven by Amphotericin B and Manx: The ramp-up of Amphotericin B launches and benefits from the Manx acquisition powered European performance; launches in France and Germany are expected in the remaining part of this fiscal year.
- Canada steady at mid-teens: Growth continues on the back of market share gains and new launches, with no challenges visible.
- ARV business stable: Pricing has been largely stable, and new South Africa tenders have not shown material pricing pressure; a recent tender went Emcure's way, and the healthy order book provides visibility for the current year and next.
- Non-ARV outgrowing ARV: The non-ARV segment continues to grow much better than ARV, supported by approvals from various regulatory agencies.
- Tenecteplase stroke opportunity: Most emerging-market approvals are for myocardial infarction, but doctor-initiated demand for the stroke indication in a few markets is yielding positive results, becoming a precursor for formally initiating registration.
Margins & Profitability
- Gross margin stable to slightly up: 60.8% vs 60.6% in Q2 FY25, with the change driven largely by product and business mix.
- EBITDA margin inching up: 19.3% vs 19.0% in Q2 FY25 and 19.2% in Q1 FY26, supported by operating leverage and productivity gains.
- Full-year target intact: Management reaffirmed the ~150 bps base-margin expansion target for the year, excluding the Sanofi diabetes and Novo deals.
- H2 expected stronger: The second half should be much better versus last year, helped by upcoming launches and domestic momentum.
- 3-4 year margin thesis: Over the medium term, as the product mix shifts toward chronic and the chronic portfolio ramps up, margin expansion should occur alongside improving MR productivity.
- In-licensing margin threshold: Management's mindset is to pursue deals that deliver mid-teens EBITDA margins and have a rub-off effect on the entire portfolio.
Balance Sheet & Capital Allocation
- Debt increased on Zuventus buyout: Debt rose because of the acquisition of the remaining minority stake in Zuventus, completed in the first week of October; the minority interest reduction will reflect for essentially the entire quarter going forward.
- Debt-free timeline pushed to end-FY27: Management now expects to be debt-free by the end of next year, an 18-24 month horizon post the Zuventus acquisition, versus the earlier guidance of debt-free in FY26 without acquisitions.
- Inventory build is launch-driven: Inventory increased in anticipation of new launches in European and Canadian markets, with H2 forecast higher; normalization is expected over the next six months.
- M&A appetite remains active: Domestic market will be active for M&A opportunities, with portfolios evaluated for entry into new segments or complementary additions in existing strong segments; bolt-on acquisitions in Canada, UK and other parts of Europe will also be considered.
- Sanofi portfolio interest: If Sanofi were to divest its diabetes portfolio, Emcure would be interested, though management called the scenario speculative.
Pipeline & In-Licensing Strategy
- In-licensing as a growth pillar: In-licensing opportunities with leading MNCs will remain an important pillar, with margins evaluated in conjunction with those opportunities.
- Bias toward own brands: Management's first preference is to keep building its own portfolio; in-licensing is pursued where it complements, and the bias is to avoid becoming disproportionately dependent on in-licensing deals.
- Lenacapavir progressing: Emcure is getting closer and should start applying for submission and approval across different countries.
- Novel molecule discussions active: The company is in talks with a few other innovator companies for their novel molecules, and the pipeline of upcoming treatment regimens is described as very healthy.
- Ureaderm launch: An upgraded line of derma products has been launched, including Ureaderm, a Canadian product with premium packaging targeting Gen Z.
Satish Mehta: "So to that extent, the bias always be in terms of ensuring that we don't become disproportionately from, what I would say, dependent on the in-licensing deals. Our endeavour is obviously to get products from our R&D and make our brands bigger."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Base margin expansion | ~150 bps improvement, excluding Sanofi diabetes and Novo deal | FY26 |
| Debt-free | Net debt zero | End of FY27 (18-24 months) |
| Organic domestic growth | Industry growth rate + 100-200 bps | Ongoing |
| Amphotericin B launches | France, Germany and other Western European countries | Remaining part of FY26 |
| Semaglutide Canada filing | File for approval in Canada | End of FY26 |
| Inventory normalization | Inventory built for launches to normalize | Next 6 months |
| In-licensing margin threshold | Mid-teens EBITDA margin deals | Ongoing |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue from operations | ₹2,270 cr, up 13.4% YoY from ₹2,002 cr in Q2 FY25 |
| Domestic business revenue | ₹1,031 cr, up 10.6% YoY |
| International business revenue | ₹1,238 cr, up 15.8% YoY |
| Europe revenue | ₹444 cr, up 22.7% YoY |
| Canada revenue | ₹348 cr, up 17.5% YoY |
| Emerging markets revenue | ₹446 cr, up 8.6% YoY |
| Gross margin | 60.8%, versus 60.6% in Q2 FY25 |
| EBITDA (excl. other income) | ₹439 cr, up 15.2% YoY |
| EBITDA margin | 19.3%, versus 19% in Q2 FY25 and 19.2% in Q1 FY26 |
| Profit after tax | ₹251 cr, up 24% YoY, highest quarterly profit |
| Net debt | ₹837 cr |
| Domestic organic growth (excl. Sanofi diabetes) | 8.5%–9% |
| Effective tax rate | 26% |
| Depreciation and amortization | ₹105 cr |
| Interest cost | ₹33 cr |